Scotiabank bullish on HEALWELL AI

Another bank has initiated coverage of HEALWELL AI (HEALWELL AI Stock Quote, Chart, News, Analysts, Financials TSX:AIDX) with a bullish target.

As reported by the Globe and Mail with, Scotiabank analyst Kevin Krishnaratne April 30 initiated coverage of AIDX with a “Sector Outperform” rating and 12-month price target of $2.50.

The analyst says the company has numerous ways to positively affect healthcare outcomes.

“We believe AIDX is in the early stages of its pursuit to drive better patient outcomes by leveraging its AI and natural language processing (NLP) expertise to detect early signals of rare and complex diseases within the noise of unstructured healthcare data across electronic medical record (EMR) systems, health information exchanges (HIEs), clinical notes, medical images, among many other sources,” Krishnaratne wrote. “Healthcare software provides defensive, recurring, and profitable global business and serves as a key distribution channel for current and future AI products.”

HEALWELL AI is a Toronto-based healthcare technology company specializing in artificial intelligence (AI) and data science for preventative care. Founded in 2012 and formerly known as MCI Onehealth Technologies, the company rebranded to HEALWELL AI in October 2023 to reflect its focus on AI-driven healthcare solutions.​

Disclosure: Cantech Letter’s Nick Waddell owns shares of HEALWELL AI.

Tagged with: aidx
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Hut 8 stock: Buy, Sell or Hold?

Roth Capital Partners analyst Bryan Baratian maintained his “Buy” rating and US$108.00 target on Hut 8 (Hut 8 Stock Quote,… [Read More]

9 hours ago

This investor explains why he loves Topicus stock

Baskin Wealth Management president and chief investment officer Barry Schwartz named Topicus.com (Topicus.com Stock Quote, Chart, News, Analysts, Financials TSX:TOI)… [Read More]

9 hours ago

RNA stock: time to buy?

On Oct. 29 Roth Capital Partners analyst Boobalan Pachaiyappan maintained his “Buy” rating and US$15.00 target on Atrium Therapeutics (Atrium… [Read More]

9 hours ago

TD raises price target on Coveo Solutions

TD Cowen analyst David Kwan raised his target on Coveo Solutions (Coveo Solutions Stock Quote, Chart, News, Analysts, Financials TSX:CVO)… [Read More]

13 hours ago

Electrovaya has an upside of 143%, this analyst says

Roth Capital Partners analyst Craig Irwin maintained his “Buy” rating and US$14.00 target on Electrovaya (Electrovaya Stock Quote, Chart, News,… [Read More]

15 hours ago

Analyst raises his price target on Kinaxis to $225.00

Stifel analyst Suthan Sukumar raised his target on Kinaxis (Kinaxis Stock Quote, Chart, News, Analysts, Financials:TSX:KXS) to $225.00 from $200.00,… [Read More]

15 hours ago